North America anti-nuclear antibody test market is expected to reach USD 920.96 million by 2025 from USD 520.46 million in 2017, at a CAGR of 7.5% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.
The key market players for North America anti-nuclear antibody test market are listed below;
Bio-Rad Laboratories, Inc.
Alere, Inc.
Trinity Biotech
Thermo Fisher Scientific Inc.
Antibodies Inc.
EUROIMMUN AG
Immuno Concepts
The market is further segmented into;
Product
Test
Disease
End-user
The North America anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the North America anti-nuclear antibody test market with 52.0% market share and is expected to reach USD 485.67 million by 2025, with the highest CAGR of 7.7% in the forecast period 2018 to 2025.
The North America anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, indirect immunofluorescence is expected to dominate the North America anti-nuclear antibody test market with 46.0% market share and is expected to reach USD 394.83 million by 2025, with the CAGR of 6.4% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 8.8% in the forecast period, and is expected to reach USD 230.71 million in 2025 from USD 118.06 million in 2017.
The North America anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sj?gren?s syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, systemic lupus erythematosus is expected to dominate the North America anti-nuclear antibody test market with 28.2% market share and is expected to reach USD 275.94 million by 2025, with the highest CAGR of 8.5% in the forecast period 2018 to 2025.
The North America anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the North America anti-nuclear antibody test market with 47.3% market share and is expected to reach USD 443.42 million by 2025, with the highest CAGR of 7.8% in the forecast period 2018 to 2025.
Based on geography, the North America anti-nuclear antibody test market is segmented into geographical regions, such as,
U.S.
Canada
Mexico
Covered in this report
The report covers the present scenario and the growth prospects of the North America anti-nuclear antibody test for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst?s time when you purchase this market report. Details are provided within the report.
